Beta Cells Get a New Line of Defense

UChicago scientists use LNP-mRNA to protect insulin-producing cells from immune attack in type 1 diabetes

6 Mar 2026

For decades, type 1 diabetes has been treated as a management problem: monitor blood sugar, inject insulin, repeat. The disease's underlying cause, an immune system that turns on the body's own insulin-producing cells, has largely been left unaddressed. A team at the University of Chicago now suggests that the same delivery technology behind mRNA vaccines might change that calculus.

Their findings, published in Cell Reports Medicine in February 2026, describe a method using lipid nanoparticles (LNPs) to ferry mRNA directly into pancreatic beta cells. Once inside, the mRNA instructs those cells to produce a protein called PD-L1, which acts as a stop signal to the immune system. Rather than destroying the beta cells, immune agents are told, in effect, to leave them alone.

The mechanism is neat, though the challenge was specificity. Injecting LNPs into the body without directing them precisely risks delivering the payload to the wrong cells. To solve this, the researchers engineered one nanoparticle variant with a peptide that latches onto the GLP-1 receptor, the same receptor targeted by blockbuster weight-loss drugs such as semaglutide. This receptor sits in abundance on beta cells, making it a useful postal address.

Both nanoparticle variants succeeded in triggering PD-L1 expression, not only in mouse beta cells but also in human beta cells grafted into mice. Among treated animals, 80 to 90 percent remained free of diabetes; in control groups, only 30 to 40 percent did.

Professor Yun Fang described the results as establishing "a strong foundation for extending the mRNA nanomedicine approach to metabolic diseases through selective targeting of insulin-producing cells." The lipid nanoparticle platform, already validated at global scale through covid-19 vaccines, lends the approach a degree of credibility that purely experimental therapies often lack.

The work remains preclinical, and the distance from mouse models to human trials is rarely short. Still, the direction is notable. mRNA technology was long associated with infectious disease; it is now being pointed at conditions where the enemy is not a virus but the body itself. For the roughly 2 million Americans with type 1 diabetes, that shift in focus may prove more consequential than any incremental improvement in insulin delivery.